Symptom trajectories in patients with panic disorder in a primary care intervention: Results from a randomized controlled trial (PARADISE)

Karoline Lukaschek¹, Thomas S. Hiller², Ulrike Schumacher³, Tobias Teismann⁴, Jörg Breitbart², Christian Brett Schneider⁵, Hans-Helmut König³, Jürgen Margraf⁴ & Jochen Gensichen¹,²

This analysis aims to identify and characterize symptom trajectories in primary care patients with panic disorder with/without agoraphobia (PD/AG) who participated in a primary care team based training involving elements of cognitive behavioural therapy (CBT). Growth Mixture Modeling was used to identify different latent classes of change in patients with PD/AG (N = 176) who underwent treatment including CBT elements. We identified three patient classes with distinct similar trajectories. Class 1 (n = 58, mean age: 46.2 years ± 13.4 years, 81% women) consisted of patients with an initially high symptom burden, but symptoms declined constantly over the intervention period. Symptoms of patients in class 2 (n = 89, mean age: 44.2 years ± 14.5 years, 67.4% women) declined rapidly at the beginning, then patients went into a plateau-phase. The third class (n = 29, mean age: 47.0 years ± 12.4 years, 65.5% women) was characterized by an unstable course and had the worse outcome. Our findings show that only a minority did not respond to the treatment. To identify this minority and refer to a specialist would help patients to get intensive care in time.

In primary care settings, up to 6.8% of patients are diagnosed with panic disorder (ICD-10: F41.0)¹. Agoraphobia (ICD-10: F40.01) is comorbid to panic disorder in 35–65% of all cases². Cognitive-behavioural therapy (CBT) can be effective for the treatment of panic disorder with or without additional agoraphobia (PD/AG) (e.g.³⁴). General practitioners (GPs) can deliver key-elements of CBT to patients with PD/AG as a first step in treatment⁵, such as psychoeducation, coping skills, cognitive restructuring, and self-managed exposure exercises⁶.

Knowledge regarding the course of PD/AG could have major implications for treatment outcome. However, it is difficult for GPs to predict the course of a patient’s illness over time. Knowledge about differences in patterns of change in the trajectories for specific subgroups of patients might enable GPs to maximize treatment outcome in individual patients and to optimize the cooperation with mental health specialists⁷⁸. Pattern recognition based on the similarities of the change trajectories shared by a group of patients can be identified via growth mixture modelling (GMM) (e.g.⁹¹⁰). Once identified as being a member of a certain group, or class, patients cannot move between classes.

Very few studies have investigated treatment response patterns in the trajectories of patients suffering from PD/AG using GMM. Lutz et al. (2014) were among the first to analyse long-term strategies in the treatment of
PD/AG. In their study of patients (N = 326) undergoing CBT, four latent patient subgroups were identified, showing clusters of change trajectories over the first few treatment sessions. The subgroup with early positive change was likely to be reliably improved at the end of the treatment. Lutz et al. concluded that early treatment changes are uniquely predictive of treatment outcome.

The present analysis was conducted within the framework of the Jena-PRARDIES study in which practice team-supported exercises with case management could better improve symptoms of PD/AG in primary care patients than treatment as usual. As part of the case management, medical assistants (MAs) periodically monitored patients by telephone using a checklist to assess symptoms and encouraging treatment adherence after a brief CBT-intervention.

The aims of the present analysis were to (1) examine associations between symptom trajectories and baseline characteristics, (2) identify and characterize treatment response patterns in the trajectories of patients suffering from PD/AG who participated in a primary care team based training involving elements of CBT.

Methods

Study design and participants. Data were derived from the “Patient Activation for Anxiety DiSordErs” (PARADISE) study, a cluster randomized controlled trial comparing a practice team-supported, self-managed exposure program for patients with PD/AG in general practices to usual care [Trial Registration: Current Controlled trials ISRCTN64669297, 07/11/2012; Deutsches Register Klinischer Studien DRKS00004386, 25/09/2012]. Patients in the intervention group showed a significant reduction in anxiety symptoms compared to patients in the control group (accepted for review). The study was approved by the ethics committee of the Friedrich- Schiller-University at the Medical Faculty (Jena, Germany). The study was planned and conducted in accordance with the guidelines of the Helsinki Declaration and with Good Clinical Practice guidelines (ICH Topic E6, 2002) as well as in accordance with the medical professional code and the Helsinki Declaration as updated in 2013. Informed consent was obtained from all participants. Details of the study design and recruiting process have been published.

To be eligible for the trial, patients had to meet the following inclusion criteria: (1) being at least 18 years of age, (2) being diagnosed with PD/AG (ICD-10: F41.0 or F40.01), (3) showing a minimum total score on the ‘Overall Anxiety and Impairment Scale’ (OASIS) of 8 points and at least two positive answers on the panic module of the ‘Patient Health Questionnaire’ (PHQ) (4), (4) having sufficient German language skills, (5) having a private telephone, (5) being capable of giving written informed consent to participate in the study. Patients were excluded if they met one or more of the following exclusion criteria: suffering from acute suicidal tendencies, acute or chronic psychosis, dependence on psychoactive substance(s), or severe physical illness; being pregnant;

intervention. Practice-team supported exposure training involved evidence-based CBT elements (psychoeducation and CBT-oriented exposure exercises) and elements derived from the chronic care model. Patients in the intervention group received a workbook containing psychoeducational information, instructions on conducting exercises, and exercise protocol forms. Over 23 weeks, GPs provided four structured sessions, the first three of which were designed to individualize the major CBT elements (psychoeducation, interoceptive exposure exercises, and situational exposure exercises). Starting from session two, patients were instructed to practice exposure exercises at least twice a week. At session four, patients were provided with relapse-prevention information. The MA periodically monitored the patients by telephone using a checklist. Data from this checklist were used to identify patterns of change over the course of treatment.

Outcome measure. The target variable for the present analysis was anxiety severity, measured by the short Overall Anxiety Severity and Impairment Scale (OASIS). The short OASIS is a 5-item measure that assesses frequency of anxiety, intensity of anxiety symptoms, behavioral avoidance, and functional impairment associated with anxiety. The original short version of the OASIS was validated in a in a large sample (N = 1,036) of primary care patients and showed good reliability and validity.

Respondents select among five different response options for each item, which are coded 0 to 4 and summed to obtain a total score (range: 0–20). A cut-score of 8 correctly classifies 87% of a clinical population sample as having an anxiety diagnosis or not. The German version of the OASIS used in this study was validated in a sample of primary care patient and showed good psychometric properties.

Statistical methods. Growth mixture modelling (GMM) is an advanced cluster analytic method that allows categorizing individuals into subgroups following similar change trajectories over a defined period. It isolates groups of patients with similar treatment response patterns or profiles over time. We identified latent subgroups (“classes”) of treatment effect trajectories by fitting GMM with patient as random factor and time, i.e. baseline and 10 visits during ongoing treatment, as fixed factor. Models incorporating practices as clusters were also considered but did not improve model fit. Since regular telephone monitoring including assessment of OASIS was part of the intervention, only patients of the intervention-arm were included in the analysis. Categorical latent variables were used to identify classes of trajectories within the patient population. Two- to five-class models were analysed, the best model was chosen based on Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) as well as by medical plausibility. We identified a two-class model with the best goodness of fit.
showed further improvement after session 2 (start of interoceptive exposure exercises), but none directly after first session (psychoeducation). Class 1 continued to improve throughout the course of the intervention. Class 2 class ends with a score of 9.9 at telephone assessment 10. In this class, a consistent pattern is missing, and its zigzag course seems rather unsteady. This phase until telephone assessment 7, from which on the OASIS score gently drops to 2.8 (telephone assessment 10).

Class 3 was more likely to live in an urban area (p **** 0.0001, Fishers exact test). Class 2 had statistically significant lower OASIS values at baseline (as shown by confidence interval). *** Differences between classes with respect to depression at baseline are statistically significant (p < 0.001, Fisher’s exact test). **** Class 3 was more likely to live in an urban area (p = 0.02, Fisher’s exact test).

According BIC, the most restrictive criterion with respect to number of classes. According AIC, the three and four-class models show a better fit, however, the latter retains mainly the three classes, but additionally segregating a fourth class containing only 3 patients with very alternating values. Consequently, from medical point of view, the three-class model shows better interpretability.

Statistical analyses were conducted using SPSS 23 for data capturing, Mplus Version 8 for GMM and SAS 9.4 for other analyses.

**Trial registration.** Current Controlled Trials [http://www.isrctn.com/ISRCTN64669297]; Deutsches Register Klinischer Studien [https://www.drks.de/drks_web/navigate.do?navigationId=TRIAL_ID=DRKS00004386].

**Results**

Our sample of primary care patients suffering from PD/AG was predominantly female (71.6%), middle aged (mean age: 45.3 ± 13.8 years), and well educated (mean years of education: 11 ± 2.9 years).

**Associations between symptom trajectories and baseline characteristics.** We identified three classes of patients with distinct similar trajectories. The class-characteristics are shown in Table 1. Class 1 had a statistically significant higher proportion of women (p = 0.004, Fisher’s exact test). We observed no differences between classes regarding mean age and years of education. Patients of class 3 were more likely to live in an urban than in a rural area. (p < 0.001, Fisher’s exact test). Class 2 had statistically significant lower OASIS values at baseline (as shown by confidence interval for the mean). Regarding depression, there were statistically significant differences between classes (p < 0.001, Fisher’s exact test); in class 3, 35.7% of the patients suffered from major depressive disorder compared to 12.2% (class 1) and 2.5% (class 2).

**Characteristics of symptom trajectories, three-class solution.** Figure 1 shows the estimated latent growth curves for the three-class solution including baseline assessment (T0) and 10 telephone assessments.

Class 1 (n = 58, mean age: 46.2 years ± 13.4 years, 81% women) had the highest estimated OASIS scores at baseline (12.4). The estimated score declined to 3.2 at telephone assessment 10. Class 1 showed improvement over almost all assessments, with a small peak at telephone assessment 4 (estimated score: 10.1).

Class 2 (n = 89, mean age: 44.2 years ± 14.5 years, 67.4% women) started with a lower estimated OASIS score about 8.8 and is marked by a steep decline to a score of 4.6 at telephone assessment 3. This is followed by a stable phase until telephone assessment 7, from which on the OASIS score gently drops to 2.8 (telephone assessment 10).

Class 3 (n = 29, mean age: 47.0 years ± 12.4 years, 65.5% women) starts at a rather high estimated OASIS score of 11.4 at baseline. In this class, a consistent pattern is missing, and its zigzag course seems rather unsteady. This class ends with a score of 9.9 at telephone assessment 10.

Sessions with the GP are indicated as vertical lines in Fig. 1. The OASIS scores declined in all classes after the first session (psychoeducation). Class 1 continued to improve throughout the course of the intervention. Class 2 showed further improvement after session 2 (start of interoceptive exposure exercises), but none directly after

| Parameter                        | Class 1 (n = 58) | Class 2 (n = 89) | Class 3 (n = 29) | Total (N = 176) |
|----------------------------------|------------------|-----------------|-----------------|----------------|
| Sex                              | Female (n/%)     | 47/81.0         | 60/67.4         | 19/65.5 **     |
| Age [years]                      | Mean             | 46.2            | 44.2            | 47             | 45.3 |
|                                  | StdDev           | 13.4            | 14.5            | 12.4           | 13.8 |
|                                  | 95%-LClm         | 42.6            | 41.2            | 42.2           | *   |
|                                  | 95%-UClm         | 49.7            | 47.3            | 51.7           | -   |
| Years of education               | Mean             | 10.9            | 11              | 11             | 11   |
|                                  | StdDev           | 2.7             | 3               | 2.7            | 2.9  |
|                                  | 95%-LClm         | 10.1            | 10.4            | 10.2           | -    |
|                                  | 95%-UClm         | 11.6            | 11.7            | 12.2           | -    |
| OASIS (baseline)                 | Mean             | 12.4            | 8.7             | 11.2           | 10.4 |
|                                  | StdDev           | 2.8             | 3.8             | 3.8            | 3.9  |
|                                  | 95%-LClm         | 11.7            | 7.9             | 9.8            | **   |
|                                  | 95%-UClm         | 13.2            | 9.5             | 12.7           | -    |
| Depression (PHQ9)                | Major depressive disorder (n/%) | 6/12.2 | 2/1.3 | 10/35.7 | *** |
|                                  | Other (n/%)      | 5/10.2          | 6/7.6           | 3/10.7         |      |
| Place of residence               | Urban (n/%)      | 12/20.7         | 22/24.7         | 8/27.6         | **** |
|                                  | Rural (n/%)      | 47/79.3         | 67/75.3         | 21/72.4        |      |

Table 1. Patients’ characteristics of all classes of the three-class solution. 95%-LClm = 95% Lower Confidence limit, 95%-UClm = 95% Upper Confidence limit, StdDev = Standard Deviation. *no statistically relevant difference. **Class 1 has a statistically significant higher fraction of women (p = 0.004, Fisher’s exact test). *** Class 2 has statistically significant lower OASIS values at baseline (as shown by confidence interval). ****Differences between classes with respect to depression at baseline are statistically significant (p < 0.001, Fisher’s exact test). ****Class 3 was more likely to live in an urban area (p = 0.02, Fisher’s exact test).
session 3 (start of situational exposure exercises). In contrast, class 3, the smallest and most unstable subgroup, showed an increase in anxiety severity after GP sessions 2 and 3.

Looking at the numbers of therapeutic contacts with the GP (Table 2), it shows that all class 3 patients (n = 29) attended sessions 1 and 2, and that only one class 3 patient missed session 3. Patients in class 1, on the other hand, were more likely to skip sessions and less likely to attend all four sessions with the GP. Class 2 has a higher proportion of patients who attended session 4 than classes 1 or 3. In general, session 4 had the highest percentage of non-attenders in all three classes.

Discussion
In our sample of predominantly female, middle-aged primary care patients with PD/AG who received four CBT-oriented GP sessions and 10 accompanying MA-telephone assessments, we identified three different trajectories: a class of patients with highest anxiety symptoms at treatment start, who responded slowly and seemed to benefit from the whole intervention programme as indicated by a continuous improvement of anxiety symptoms (class 1); a class of patients with lowest anxiety levels who responded early to treatment, then went into a plateau-phase and ended with a final improvement similar to class 1 (class 2); a third class that did not seem to benefit from the intervention programme as indicated by a fluctuating anxiety symptom burden and only minimal improvement over time (class 3).
A previous study using GMM to identify trajectories of anxiety found four patterns of early treatment response comparable to ours: a rapidly improving group, an initially highly symptomatic and slowly improving group, an initially low symptom and slowly improving group, and an early deteriorating group. These response profiles were predictive of treatment outcome and, to a lesser extent, the number of sessions attended. In our study, class 1 was less likely to complete all four sessions with the GP, probably because these patients’ condition continued to improve. On the other hand, class 3 most reliably kept their sessions, probably due to help-seeking behaviour caused by these patients’ bad condition. Due to the high risk for treatment drop-out of such patients showing no improvement, only few other studies that investigated change patterns with a cluster analytic method reported this specific subgroup. This subgroup is of clinical importance, because it clearly showed the worst treatment outcomes and still had high levels of symptom severity at the end of the intervention. The non-response to the treatment became obvious for the GP around session 3, but was in the looming after session 2 as indicated by the unstable course. GPs should act quickly and refer these patients to a mental health specialist (“stepped care”); obviously, they cannot be helped with a low-threshold minimal treatment administered by GPs. This group was also burdened with the highest percentage of major depressive disorder at baseline. The combination of high anxiety levels and major depressive disorder might be a further indication for referral to a specialist.

Monitoring by the MA and sessions with the GP had a positive effect on class 1. Regarding class 2, GP sessions 3 and 4 apparently did not have an influence; we assume that monitoring by the MA prevented a deterioration of PD/AG. However, we cannot exclude that a more intense case management, e.g. by a psychotherapist, could have led to further improvement of class 2.

**Strengths and limitations.** The strengths of this study are its embedding within the framework of the thoroughly designed Jena-PARADIES study and the use of a well-established anxiety instrument. In contrast to other models, e.g. the staging model, using GMM to identify classes can provide information whether an intervention is effective, while stages provide information on the individual disease burden. A limitation of the present analysis relates to the interpretation of the early positive response pattern. It cannot be ruled out that early response was also partially due to factors such as regression to the mean or placebo effects. To eliminate these alternative explanations, it would be necessary to investigate additional change patterns among an untreated group of patients with PD/AG, and compare the patients within early positive change classes. In the present analysis, this was not possible, because we do not have data on trajectories in the control group.

**Conclusion**

Our findings show that for the majority of anxiety patients a low-threshold treatment administered by the GP is adequate. Only a minority did not respond to the treatment. To identify this minority and refer to a specialist would help patients to get intensive care in time.

**Data Availability**

The authors confirm that, for approved reasons, access restrictions apply to the data underlying the findings and thus they cannot be made freely available in the manuscript, the Supplemental Files, or a public repository. The data are subject to national data protection laws and restrictions were imposed by the Ethics Committees to ensure data privacy of the study participants. However, they can be applied for through an individual project agreement with the PI of the study, Prof. Gensichen (Jochen.Gensichen@med.uni-muenchen.de).

**References**

1. Kroenke, K., Spitzer, R. L., Williams, J. B., Monahan, P. O. & Lowe, B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med* **146**, 317–325 (2007).
2. Wittchen, H. U. *et al.* The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* **21**, 655–679, https://doi.org/10.1016/j.euroneuro.2011.07.018 (2011).
3. Aaronson, C. J. *et al.* Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapy. *J Clin Psychiatry* **69**, 418–424 (2008).
4. Hofmann, S. G. & Smits, J. A. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. *J Clin Psychiatry* **69**, 621–632 (2008).
5. Dengler, W., Seilermann, H. K. *Praxisleitlinien in Psychiatrie, Psychotherapie, Band 2: Leitlinien zu Diagnostik und Therapie von Angststörungen.* (Steinkopff, 2000).
6. Gensichen, J.* et al.* Evaluation of a practice team-supported exposure training for patients with panic disorder with or without agoraphobia in primary care - study protocol of a cluster randomised controlled superiority trial. *Trials* **15**, 112, https://doi.org/10.1186/1745-6159-15-112 (2014).
7. Lutz, W. *et al.* Patterns of early change and their relationship to outcome and early treatment termination in patients with panic disorder. *J Consult Clin Psychol* **82**, 287–297, https://doi.org/10.1037/a0035535 (2014).
8. Kazdin, A. E. Mediators and mechanisms of change in psychotherapy research. *Annu Rev Clin Psychol* **3**, 1–27, https://doi.org/10.1146/annurev.clinpsy.3.022806.091432 (2007).
9. Nagn, D. S. & Odgers, C. L. Group-based trajectory modeling in clinical research. *Annu Rev Clin Psychol* **6**, 109–138, https://doi.org/10.1146/annurev.clinpsy.121208.131413 (2010).
10. Cuipers, P., van Lier, P. A., van Straten, A. & Donker, M. Examining differential effects of psychological treatment of depressive disorder: an application of trajectory analyses. *J Affect Disord* **89**, 137–146, https://doi.org/10.1016/j.jad.2005.09.001 (2005).
11. Gensichen, J.* et al.* On behalf of the Jena-PARADIES study group: Panic disorder in primary care: the effects of a team-based intervention—a cluster randomized trial. *Dtsch Arztebl Int* **116**, 159–166 (2019).
12. Hilger, T. S.*, et al.* The Jena Anxiety Monitoring List (JAMoL) - a tool for the evidence-based treatment of panic disorder with or without agoraphobia in primary care. *Z Evid Fortbild Qual Gesundhws* **131–132**, 28–37, https://doi.org/10.1002/zefq.2018.02.003 (2018).
13. Norman, S. B., Cissell, S. H., Means-Christensen, A. J. & Stein, M. B. Development and validation of an Overall Anxiety Severity And Impairment Scale (OASIS). *Depress Anxiety* **23**, 245–249, https://doi.org/10.1002/da.20182 (2006).
14. Spitzer, R. L., Kroenke, K. & Williams, J. B. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. *JAMA* **282**, 1737–1744 (1999).
15. Margraf, J., Barlow, D. H., Clark, D. M. & Telch, M. J. Psychological treatment of panic: Work in progress on outcome, active ingredients, and follow-up. *Behav Res Ther* **31**, 1–8 (1993).

16. Wagner, E. H. *et al.* Improving chronic illness care: translating evidence into action. *Health Aff (Millwood)* **20**, 64–78, https://doi.org/10.1377/hlthaff.20.6.64 (2001).

17. Norman, S. R. *et al.* Psychometrics of a brief measure of anxiety to detect severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). *J Psychiatr Res* **45**, 262–268, https://doi.org/10.1016/j.jpsychires.2010.06.011 (2011).

18. Campbell-Sills, L. *et al.* Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). *J Affect Disord* **112**, 92–101, https://doi.org/10.1016/j.jad.2008.03.014 (2009).

19. Hiller, T. *et al.* In 48. *Kongress für Allgemeinmedizin und Familienmedizin* (German Medical Science GMS Publishing House, Hamburg, 2014).

20. Lotz, W. *et al.* Predicting change for individual psychotherapy clients on the basis of their nearest neighbors. *J Consult Clin Psychol* **73**, 904–913, https://doi.org/10.1037/0022-006X.73.5.904 (2005).

21. Morral, A. R., Iuchi, M. Y., Belding, M. A. & Lamb, R. J. Natural classes of treatment response. *J Consult Clin Psychol* **65**, 673–685 (1997).

22. Cosci, F. & Fava, G. A. Staging of mental disorders: systematic review. *Psychother Psychosom* **82**, 20–34, https://doi.org/10.1159/000342243 (2013).

23. Stewart, J. W. *et al.* Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. *Arch Gen Psychiatry* **55**, 334–343 (1998).

**Acknowledgements**

The PARADIES-trial was funded by the German Federal Ministry of Education and Research (BMBF; grant-number: 01GY1146). The funding source was not involved in the interpretation of the data, in the writing of the report and in the decision to submit the article for publication. The authors would like to thank the Jena-PARADISE Study Group (www.uniklinikum-jena.de/allgemeinmedizin/Forschung/Abgeschlossene+Projekte/Jena_Paradies-p-80.html) for their support. This trial was funded by the German Federal Ministry of Education and Research (BMBF; Grant-Number: 01GY1146).

**Author Contributions**

K.L. writing of the main manuscript text; preparing of figures and tables; critical revision; T.S.H. data collection; statistical analysis; critical revision; U.S. statistical analysis, preparing of figures and tables critical revision; T.T. critical revision; J.B. data collection; critical revision; U.S. statistical analysis; preparing of figures and tables critical revision; T.T. critical revision; J.B. data collection; critical revision; C.B. critical revision; H.H.K. conception and design; critical revision; J.M. clinical content; critical revision; J.G. initial conception and design; data collection; statistical analysis; critical revision. All authors reviewed and approved the final manuscript.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-43487-x.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.